Clinical trials: Hepatitis; Epidemic
Hepatitis C
Boceprevir and Ucalm (St John&Apos;s Wort)
The purpose of the study is to look at whether taking a new medication for hepatitis C (boceprevir) together with a herbal remedy commonly used for the treatment of depression (SJW) has any effect on the levels of boceprevir in…
- Trial name
- NCT01663922
- Testing
- Boceprevir, St John's Wort
- Where
- United Kingdom
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- St Stephens Aids Trust
Chronic Hepatitis B
APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B
This study is a Multiple Ascending Dose study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of APG-1387 in Chronic Hepatitis B Patients.
- Trial name
- NCT03585322
- Testing
- APG-1387 for Injection
- Where
- 2 sites in China
- Volunteers
- 49 people
- Sponsor
- Ascentage Pharma Group Inc.
Hepatitis C, Chronic
PegIntron Injection Surveillance Plan (Study P04123)
Surveillance will be conducted at digestive departments of internal medicine in university or general hospitals where participants with chronic hepatitis C are generally treated.
- Trial name
- NCT00723931
- Testing
- Peginterferon alfa-2b (SCH 54031)
- Volunteers
- 1,267 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatocellular Carcinoma, Hepatitis B
Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma
To evaluate the impact of liver fibrosis and other variables [e.g., age, sex, virological response (VR), and previous resistance to nucleoside/nucleotide analogue (NUC) therapy] on Hepatocellular carcinoma incidence in an Italian…
- Trial name
- HBV/HCC (NCT02025842)
- Volunteers
- 306 people
- Sponsor
- Azienda Ospedaliera San Camillo Forlanini
Hepatitis C, Chronic, Hepatitis C
Post-marketing Surveillance of Children With Chronic Hepatitis C Treated With Intron A (Vial or Pen) and Rebetol (Study P04397)(TERMINATED)
The objective of the study is to assess the safety and efficacy of Intron A (3 Mio I.E./m2, 3 times per week) and Rebetol (15 mg/kg/day) in children aged 3 to 17, treated in common medical practice at 10 sites in Germany.
- Trial name
- NCT00727077
- Testing
- IntronA (interferon alfa-2b; SCH 30500), Rebetol (ribavirin; SCH 18908)
- Volunteers
- 3 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers
The purpose of this study is to evaluate the effect of telaprevir on the results of electrocardiograms in healthy volunteers. An electrocardiogram is an electric recording of the heart.
- Trial name
- NCT00973388
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Hepatitis B Reactivation
HBV Vaccine in Anti-core Positive Donors After LT
Anti-HBc positive liver donors frequently have occult HBV infection, and several studies in HBsAg-negative subjects have shown that there is often the detection in the liver of covalently closed circular DNA (cccDNA).
- Trial name
- NCT04442841
- Testing
- Hepatitis B vaccine
- Where
- Spain
- Volunteers
- 114 people
- Sponsor
- Hospital Clinic of Barcelona
Hepatitis B, Hepatitis D
Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)
Patients with chronic HBV infection will receive either ARC-520 alone or ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF) and/or pegylated interferon (PEG IFN) alpha 2a therapy, and be…
- Trial name
- MONARCH (NCT02577029)
- Testing
- ARC-520, entecavir, pegylated interferon alpha 2a
- Where
- 33 sites in Australia, Bulgaria and 6 more
- Volunteers
- 79 people
- Sponsor
- Arrowhead Pharmaceuticals
Hepatitis C
Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin
Genotype 1 hepatitis C virus (HCV) patients who did not respond (did not lose virus during treatment) or relapsed (virus went away on treatment but came back after treatment was stopped) after treatment with at least twelve weeks…
- Trial name
- NCT00207402
- Testing
- rosiglitazone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Brooke Army Medical Center
Chronic Hepatitis C Virus Infection
ٍٍSofosbuvir/Simeprevir/Daclatasvir/Ribavirin and HCV Genotype 4-infected Egyptian Experienced Participants
Experienced participants who had HCV GT4 infection were treated with Sofosbuvir/Simeprevir/Daclatasvir/Ribavirin (SOF/SMV/DCV/RBV)
- Trial name
- NCT04387539
- Testing
- SOF/SMV/DCV/RBV
- Where
- Egypt
- Volunteers
- 94 people
- Sponsor
- Beni-Suef University
Acute-on-Chronic Liver Failure, Hepatitis B, Chronic
Prediction Model Based on Computed Tomography Liver Volume for the Short-term Mortality in Hepatitis B Related Acute-on-Chronic
HBV-related acute-on-chronic liver failure (HBV-ACLF) deteriorates rapidly with a high short-term mortality. Early identification and accurate prognostic prediction was critical to improve survival rate.
- Trial name
- NCT03977857
- Where
- China
- Volunteers
- 486 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Chronic Hepatitis C
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Treatment with peginterferon plus daily low dose (800 mg) or weight-based ribavirin (800-1400 mg) for 24 to 48 weeks has achieved 70-93% sustained virologic response (SVR) rates in patients with genotype 2 or 3 chronic hepatitis…
- Trial name
- NCT00532701
- Testing
- Peg-IFN + WB RBV for 16 weeks, Peg-IFN + LD RBV for 16 weeks, Peg-IFN + WB RBV for 24 weeks
- Where
- 9 sites in Taiwan
- Volunteers
- 880 people
- Sponsor
- National Taiwan University Hospital
Chronic Hepatitis B
A Phase 1 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in Chronic Hepatitis B Patients
This study is SAD(Single Ascending Dose)/MAD(Multiple Ascending Dose) study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin) in Chronic Hepatitis B…
- Trial name
- NCT02569372
- Testing
- GC1102
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Green Cross Corporation
Chronic Infection
Orange Juice Consumption in Patients With Hepatitis C
This study aimed to verify whether orange juice, source of citrus flavonoids and vitamin C, may contribute to the treatment of patients with chronic hepatitis C.
- Trial name
- NCT03026569
- Testing
- Orange juice (500 mL/d)
- Where
- Brazil
- Volunteers
- 43 people
- Sponsor
- São Paulo State University
Hepatitis C
ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing
Hepatitis C virus (HCV) infection has become the leading fatal infectious disease in the United States. Approximately 75% of individuals who have been infected with HCV are chronically infected with the virus.
- Trial name
- NCT03767231
- Testing
- Xpert HCV Viral Load Finger-stick Point-of-Care test (Cepheid)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Johns Hopkins University
Chronic Hepatitis B, Chronic Hepatitis D
Lamivudine for Chronic Hepatitis B
Chronic hepatitis B is a disease of the liver caused by the hepatitis B virus. It affects nearly 1 million Americans. Approximately 25% of patients with chronic hepatitis B will develop liver cirrhosis and 5% of patients will…
- Conditions
- Chronic Hepatitis B, Chronic Hepatitis D, Glomerulonephritis, Polyarteritis Nodosa
- Trial name
- NCT00001457
- Testing
- Lamivudine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C
Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for the Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 (P08599)
This study is designed to assess the safety and tolerability of boceprevir dosed 800 mg three times daily (TID) orally (PO) in combination with Peginterferon alfa-2b (PEG2b) 1.5 mcg/kg once a week (QW) administered subcutaneously…
- Trial name
- NCT01641666
- Testing
- Boceprevir, Peginterferon Alfa-2b 1.5 mcg/kg/week, Ribavirin
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis E
Long-term Effectiveness of a Recombinant Hepatitis E Vaccine
This test-negative study is designed to evaluate the long-term effectiveness of hepatitis E vaccine (Hecolin®) and to explore the prevalence of rat hepatitis E in Dongtai City.
- Trial name
- NCT05976594
- Testing
- serology and virology detection of hepatitis E virus
- Where
- China
- Volunteers
- 2,900 people
- Sponsor
- Xiamen University
Advanced HBV-Related Hepatocellular Carcinoma
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of BRII-5395 in Combination With Sintilimab and Bevacizumab in Advanced Hepatitis B Virus Related Hepatocellular Carcinoma
This early phase (Phase 1) study will evaluate BRII 5395, administered in combination with two approved anticancer agents, sintilimab and bevacizumab, in patients with advanced liver cancer caused by chronic hepatitis B virus…
- Trial name
- NCT07557251
- Testing
- BRII-5395, Sintilimab, Bevacizumab
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Autoimmune Hepatitis
Mindfulness - Based Stress Reduction and the Relationship on Inflammation in Autoimmune Hepatitis
The study is a 'pilot study' to assess the effect of a mindfulness-based stress reduction (MBSR) intervention on patients with autoimmune liver disease specifically autoimmune hepatitis type I.
- Trial name
- NCT02950077
- Testing
- mindfulness based stress reduction
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Yale University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.